Reneo Pharmaceuticals Announces Poster Presentation at Upcoming Scientific Meetings
October 25 2023 - 7:50AM
Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage
pharmaceutical company focused on the development and
commercialization of therapies for patients with rare genetic
mitochondrial diseases, today announced the company will present a
poster titled “Selective peroxisome proliferator-activated receptor
(PPAR) delta (δ) agonist, mavodelpar, improves cellular
bioenergetics in fibroblasts from patients with mitochondrial
complex I deficiency” at the following upcoming scientific
meetings.
PittGene MeetingDate: Wednesday, October 25,
2023, at 2:00-2:45pm ETLocation: University Club at University of
Pittsburgh, Pittsburgh, PAPresenter: Bianca Seminotti, PhD
Translational Research in Mitochondria, Metabolism,
Aging and Disease (TRiMAD) Meeting 2023Date: Monday,
November 6, 2023, at 5:30-7:00pm ETLocation: University Club at
University of Pittsburgh, Pittsburgh, PAPresenter: Bianca
Seminotti, PhD
In this presentation, Reneo and collaborators will report
findings which demonstrate that the bioenergetic deficiencies and
mitochondrial dysfunction observed in CI-deficient patient
fibroblasts can potentially be alleviated by treatment with
mavodelpar, a potent and selective PPARδ agonist. Furthermore,
because mavodelpar activation results in increased transcription of
genes involved in mitochondrial biogenesis, fatty acid oxidation
and energy production in the form of ATP, these results provide
mechanistic evidence for the potential of mavodelpar as a
therapeutic option in this and similar types of primary
mitochondrial myopathies (PMM).
Mavodelpar is an investigational drug product candidate that is
under clinical investigation, and which has not yet been approved
for marketing by the U.S. Food and Drug Administration, European
Medicines Agency, or any other regulatory agency.
About Reneo PharmaceuticalsReneo is a
clinical-stage pharmaceutical company focused on the development
and commercialization of therapies for patients with rare genetic
mitochondrial diseases, which are often associated with the
inability of mitochondria to produce adenosine triphosphate (ATP).
Our lead product candidate, mavodelpar (REN001), is a potent and
selective agonist of the peroxisome proliferator-activated receptor
delta (PPARδ). Mavodelpar has been shown to increase transcription
of genes involved in mitochondrial function, increase fatty acid
oxidation, and may increase production of new mitochondria. For
additional information, please see reneopharma.com.
Contacts:
Danielle Spangler Investor Relations Reneo
Pharmaceuticals, Inc. dspangler@reneopharma.com
Matthew Purcell, Pharm.D.Media Inquiries Russo Partners,
LLC matthew.purcell@russopartnersllc.com
Reneo Pharmaceuticals (NASDAQ:RPHM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Reneo Pharmaceuticals (NASDAQ:RPHM)
Historical Stock Chart
From Jul 2023 to Jul 2024